Molecular therapy in the microRNA era

T Wurdinger, FF Costa - The pharmacogenomics journal, 2007 - nature.com
MicroRNAs (miRNAs) consist of a growing class of non-coding RNAs (ncRNAs) that
negatively regulate the expression of genes involved in development, differentiation …

MicroRNA therapeutics in neurological disease

DS Greenberg, H Soreq - Current pharmaceutical design, 2014 - ingentaconnect.com
Developing microRNA therapeutics for neurological diseases is both a promising
opportunity and an extremely challenging topic for several reasons. The promise stems from …

[HTML][HTML] Stroke-induced microRNAs: The potential therapeutic role for stroke

P Wu, X Zuo, A Ji - Experimental and therapeutic …, 2012 - spandidos-publications.com
Stroke is one of the leading causes of death and disability worldwide. In past decades,
researchers have studied the physiopathology and biochemistry of stroke, but knowledge of …

miRNAs as therapeutic targets in inflammatory disease

Q Lu, R Wu, M Zhao, A Garcia-Gomez… - Trends in pharmacological …, 2019 - cell.com
In the past decade, we have witnessed considerable developments in understanding the
roles and functions of miRNAs. In parallel, the identification of alterations in miRNA …

MicroRNAs: newcomers into the ALS picture

C Volonté, S Apolloni, C Parisi - CNS & Neurological Disorders …, 2015 - ingentaconnect.com
Amyotrophic lateral sclerosis (ALS) causes neurodegeneration of both upper and lower
motor neurons and progressive muscle impairment, atrophy and death within approximately …

Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease

A Bortolozzi, S Manashirov, A Chen, F Artigas - Pharmacology & …, 2021 - Elsevier
Remarkable advances in understanding the role of RNA in health and disease have
expanded considerably in the last decade. RNA is becoming an increasingly important …

Midbrain dopamine neurons in Parkinson׳ s disease exhibit a dysregulated miRNA and target-gene network

CE Briggs, Y Wang, B Kong, TUW Woo, LK Iyer… - Brain research, 2015 - Elsevier
The degeneration of substantia nigra (SN) dopamine (DA) neurons in sporadic Parkinson׳ s
disease (PD) is characterized by disturbed gene expression networks. Micro (mi) RNAs are …

[HTML][HTML] miR-182-5p and miR-183-5p act as GDNF mimics in dopaminergic midbrain neurons

AE Roser, LC Gomes, R Halder, G Jain, F Maass… - … Therapy-Nucleic Acids, 2018 - cell.com
Parkinson's disease (PD) is the second-most-frequent neurodegenerative disorder
worldwide. One major hallmark of PD is the degeneration of dopaminergic (DA) neurons in …

[HTML][HTML] The path to microRNA therapeutics in psychiatric and neurodegenerative disorders

AWS Chan, J Kocerha - Frontiers in genetics, 2012 - frontiersin.org
The microRNA (miRNA) class of non-coding RNAs exhibit a diverse range of regulatory
roles in neuronal functions that are conserved from lower vertebrates to primates. Disruption …

[HTML][HTML] miRNAs: The road from bench to bedside

G Iacomino - Genes, 2023 - mdpi.com
miRNAs are small noncoding RNAs that control gene expression at the posttranscriptional
level. It has been recognised that miRNA dysregulation reflects the state and function of cells …